From Breakingviews - Sunken oil tanker merger leaves CEO adrift
Investors’ apparent surprise came even though Euronav’s main shareholder, family-controlled Compagnie Maritime Belge, increased its stake to more than 25%, with the apparent goal of crippling the deal.
That’s odd because the terms looked increasingly favourable to Euronav shareholders: Frontline’s net asset value had jumped 43% between the deal’s announcement and December, against 21% for its Belgian target, Jefferies reckoned. De Stoop is now stuck running a smaller company than he had hoped, and with a large investor whose plans for its stake are unclear. The next question is how long they can both stay in the same boat.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Oil tanker groups Frontline and Euronav scrap $4.2 billion mergerOil tanker company Frontline said on Monday a $4.2 billion deal to merge with rival Euronav NV was terminated, a combination which would have created the world's largest publicly listed tanker company.
続きを読む »
Breakingviews - Jack Ma's Ant is China tech's tiniest bellwetherJack Ma is leading China’s consumer internet out of the sin bin. After his fintech champion Ant said its founder will cede control, shares in affiliate Alibaba , rose 7% in Hong Kong on Monday morning. It may mark the end of Ant's campaign to placate regulators after they derailed the group's $37 billion initial public offering in late 2020. It’s not clear whether it marks much more than that.
続きを読む »
Breakingviews - Smarter taxes could ease UK productivity crisisBritain is on the brink of a recession that will last into 2024, according to the Bank of England. But the country’s malaise runs deeper than a cyclical contraction. Since 2008, the UK has suffered a sharp slowdown in productivity. To remedy that, Prime Minister Rishi Sunak will need to take unpopular measures.
続きを読む »
Breakingviews - AstraZeneca’s new deal is smarter than it looksOn the face of it, Pascal Soriot’s new deal ought to raise his shareholders’ blood pressure. The boss of $221 billion pharma giant AstraZeneca has agreed to buy CinCor Pharma for up to $1.8 billion. Yet paying $26 in cash per CinCor share and an extra $10 per share if a key drug is submitted for regulatory approval represents a 206% bump to CinCor’s closing share price on Friday. That’s around four times the average premium on recent industry deals.
続きを読む »
Breakingviews - Brazil protests expose lack of U.S. risk premiumImages of thousands of supporters of former President Jair Bolsonaro storming Brazil’s Congress, Supreme Court and presidential palace on Sunday made for uncomfortable viewing in the United States. They were disconcertingly similar to the invasion of America’s Capitol by followers of Donald Trump two years before. For investors, however, the two countries carry very different financial risks. That’s based on a mix of rationality and perhaps some complacency.
続きを読む »